Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Hydrocortisone. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 known ✓ | P04150 | 3/20 | 0.91 |
| ▸ | HIF1A | Q16665 | 12/20 | 0.91 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.91 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.91 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.91 |
| ▸ | SERPINA6 | P08185 | 3/20 | 0.91 |
| ▸ | PGR | P06401 | 3/20 | 0.91 |
| ▸ | NR3C2 | P08235 | 3/20 | 0.91 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.91 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.91 |
| ▸ | SHBG | P04278 | 2/20 | 0.91 |
| ▸ | MAPT | P10636 | 2/20 | 0.91 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.91 |
| ▸ | LMNA | P02545 | 3/20 | 0.73 |
| ▸ | AR | P10275 | 1/20 | 0.72 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.72 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.67 |
| ▸ | TSHR | P16473 | 2/20 | 0.67 |
| ▸ | BLM | P54132 | 1/20 | 0.67 |
| ▸ | POLB | P06746 | 1/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrocortisone SCHEMBL180227 | 1.00 | HIF1A (0.91) | HIF1AHSD17B10SMN1; SMN2CYP2C19NR3C1 | |
| Hydrocortisone SCHEMBL26659908 | 0.99 | HIF1A (0.89) | HIF1AHSD17B10SMN1; SMN2CYP2C19NR3C1 | |
| Hydrocortisone SCHEMBL2253854 | 0.98 | HIF1A (0.88) | HIF1AHSD17B10SMN1; SMN2CYP2C19NR3C1 | |
| Hydrocortisone SCHEMBL1807734 | 0.96 | HIF1A (0.83) | HIF1AHSD17B10SMN1; SMN2CYP2C19NR3C1 | |
| Hydrocortisone SCHEMBL122188 | 0.96 | HIF1A (0.83) | HIF1AHSD17B10SMN1; SMN2CYP2C19NR3C1 | |
| Hydrocortisone SCHEMBL3999007 | 0.95 | HIF1A (0.96) | HIF1AHSD17B10SMN1; SMN2CYP2C19NR3C1 | |
| Hydrocortisone SCHEMBL24900238 | 0.95 | HIF1A (1.00) | HIF1AHSD17B10SMN1; SMN2CYP2C19NR3C1 | |
| Hydrocortisone SCHEMBL143923 | 0.95 | HIF1A (1.00) | HIF1AHSD17B10SMN1; SMN2CYP2C19NR3C1 | |
| Hydrocortisone SCHEMBL19465688 | 0.95 | HIF1A (1.00) | HIF1AHSD17B10SMN1; SMN2CYP2C19NR3C1 | |
| Hydrocortisone SCHEMBL6932400 | 0.95 | HIF1A (1.00) | HIF1AHSD17B10SMN1; SMN2CYP2C19NR3C1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113557020-A | Compositions comprising CRAC inhibitors and corticosteroids and methods of use thereof | 瑞真药业公司 | 2021-10-26 | — | — | CN | claimed |
| CN-108368179-B | Methods of treating CEA positive cancers using PD-1 axis binding antagonists and anti-CEA/anti-CD 3 bispecific antibodies | 豪夫迈·罗氏有限公司 | 2022-08-23 | — | — | CN | disclosed |
| CN-114728011-A | Preparations comprising steroid dimers and uses thereof in therapeutic agent delivery | 波纹疗法公司 | 2022-07-08 | — | — | CN | disclosed |
| CN-114599406-A | Surface coatings and implantable devices comprising dimeric steroid prodrugs and uses thereof | 波纹疗法公司 | 2022-06-07 | — | — | CN | disclosed |
| CN-113727698-A | Pharmaceutical dosage form for administration to mucosa and method for producing the same | 伊斯凯普公司 | 2021-11-30 | — | — | CN | disclosed |
| CN-113710706-A | Administration for anti-TIGIT antibody and anti-CD 20 antibody or anti-CD 38 antibody treatment | 豪夫迈·罗氏有限公司 | 2021-11-26 | — | — | CN | disclosed |
| CN-113453670-A | Transforaminal delivery of steroids and macromolecules | 乔·斯图丁 | 2021-09-28 | — | — | CN | disclosed |
| CN-112410298-A | Enhanced stem cell compositions | 菲特治疗公司 | 2021-02-26 | — | — | CN | disclosed |
| CN-112375734-A | Enhanced stem cell compositions | 菲特治疗公司 | 2021-02-19 | — | — | CN | disclosed |
| CN-104066837-B | Enhanced stem cell compositions | 菲特治疗公司 | 2020-12-08 | — | — | CN | disclosed |
| CN-105828837-B | Methods of treating cancer with PD-1 axis binding antagonists and taxanes | 豪夫迈·罗氏有限公司 | 2020-10-27 | — | — | CN | disclosed |
| CN-111630387-A | Methods and devices for detecting preeclampsia-related biomarkers | 艾基诺米公司 | 2020-09-04 | — | — | CN | disclosed |
| CN-111527098-A | Phosphoramidate diphosphate salt of nucleoside as anticancer compound | 努卡那公共有限公司 | 2020-08-11 | — | — | CN | disclosed |
| CN-111148755-A | Recombinant modified fibroblast growth factor and therapeutic uses thereof | 特里福伊尔治疗公司 | 2020-05-12 | — | — | CN | disclosed |
| CN-103228273-B | Monovalent metal cation dry powder for inhalation | 普马特里克斯营业公司 | 2017-04-05 | — | — | CN | disclosed |
| CN-103228273-A | Monovalent metal cation dry powder for inhalation | PULMATRIX INC | 2013-07-31 | — | — | CN | disclosed |
| CN-103200938-A | Dry powder formulations and methods for treating pulmonary diseases | PULMATRIX INC | 2013-07-10 | — | — | CN | disclosed |
| US-20090233892-A1 | Topical Compositions Comprising Hydrocortisone Butyrate | GLENMARK GENERICS LTD (IN) | 2009-09-17 | — | — | US | disclosed |
| US-5023251-A | Storage stability; skin disorders | BEIERSDORF AG (DE) | 1991-06-11 | — | — | US | disclosed |
| US-4902682-A | W/O cream containing hydrocortisone diester | BEIERSDORF AG (DE) | 1990-02-20 | — | — | US | disclosed |